CAD 0.03
(-14.29%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.08 Million CAD | 14.24% |
2022 | 1.82 Million CAD | -28.02% |
2021 | 2.54 Million CAD | -9.26% |
2020 | 2.79 Million CAD | 489.47% |
2019 | 474.92 Thousand CAD | 37.25% |
2018 | 346.03 Thousand CAD | 246.87% |
2017 | 99.76 Thousand CAD | 0.0% |
2016 | - CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q3 | 3.4 Million CAD | 11.08% |
2024 Q2 | 3.06 Million CAD | 33.86% |
2024 Q1 | 2.29 Million CAD | 9.74% |
2023 Q4 | 2.08 Million CAD | 38.5% |
2023 FY | 2.08 Million CAD | 14.24% |
2023 Q1 | 1.69 Million CAD | -7.22% |
2023 Q2 | 1.72 Million CAD | 1.94% |
2023 Q3 | 1.5 Million CAD | -12.78% |
2022 Q1 | 2.66 Million CAD | 4.81% |
2022 Q3 | 1.61 Million CAD | 7.45% |
2022 FY | 1.82 Million CAD | -28.02% |
2022 Q4 | 1.82 Million CAD | 13.01% |
2022 Q2 | 1.5 Million CAD | -43.45% |
2021 Q1 | 2.72 Million CAD | -2.7% |
2021 FY | 2.54 Million CAD | -9.26% |
2021 Q4 | 2.54 Million CAD | 180.54% |
2021 Q3 | 905.51 Thousand CAD | 73.99% |
2021 Q2 | 520.44 Thousand CAD | -80.89% |
2020 Q2 | 812.29 Thousand CAD | 52.99% |
2020 Q3 | 422.18 Thousand CAD | -48.03% |
2020 Q4 | 2.79 Million CAD | 563.12% |
2020 FY | 2.79 Million CAD | 489.47% |
2020 Q1 | 530.93 Thousand CAD | 11.79% |
2019 Q4 | 474.92 Thousand CAD | 50.25% |
2019 Q1 | 325.88 Thousand CAD | -5.83% |
2019 Q2 | 884.76 Thousand CAD | 171.5% |
2019 FY | 474.92 Thousand CAD | 37.25% |
2019 Q3 | 316.09 Thousand CAD | -64.27% |
2018 Q3 | 230.93 Thousand CAD | 18.26% |
2018 FY | 346.03 Thousand CAD | 246.87% |
2018 Q2 | 195.27 Thousand CAD | 15.54% |
2018 Q1 | 169 Thousand CAD | 69.41% |
2018 Q4 | 346.03 Thousand CAD | 49.84% |
2017 Q3 | 81.12 Thousand CAD | 8.16% |
2017 FY | 99.76 Thousand CAD | 0.0% |
2017 Q4 | 99.76 Thousand CAD | 22.98% |
2017 Q2 | 75 Thousand CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aion Therapeutic Inc. | 2.93 Million CAD | 28.862% |
Ayurcann Holdings Corp. | 14.31 Million CAD | 85.411% |
Blueberries Medical Corp. | 470.72 Thousand CAD | -343.776% |
The BC Bud Corporation | 626 Thousand CAD | -233.697% |
BioNxt Solutions Inc. | 6.55 Million CAD | 68.109% |
CordovaCann Corp. | 11.29 Million CAD | 81.499% |
Christina Lake Cannabis Corp. | 8.5 Million CAD | 75.427% |
Captor Capital Corp. | 28.76 Million CAD | 92.738% |
City View Green Holdings Inc. | 3.73 Million CAD | 44.04% |
1CM Inc. | 9.42 Million CAD | 77.833% |
Global Hemp Group Inc. | 5.82 Million CAD | 64.139% |
Greenway Greenhouse Cannabis Corporation | 21.17 Million CAD | 90.134% |
IM Cannabis Corp. | 35.11 Million CAD | 94.051% |
Lobe Sciences Ltd. | 2.45 Million CAD | 15.07% |
Maple Leaf Green World Inc. | 10.08 Million CAD | 79.278% |
Mountain Valley MD Holdings Inc. | 258 Thousand CAD | -709.672% |
Nextleaf Solutions Ltd. | 4.4 Million CAD | 52.56% |
Ovation Science Inc. | 728.99 Thousand CAD | -186.554% |
Pharmadrug Inc. | 2.92 Million CAD | 28.594% |
RAMM Pharma Corp. | 2.83 Million CAD | 26.329% |
RIV Capital Inc. | 275.63 Million CAD | 99.242% |
Revive Therapeutics Ltd. | 3.4 Million CAD | 38.631% |
Red White & Bloom Brands Inc. | 364.63 Million CAD | 99.427% |
SLANG Worldwide Inc. | 37.58 Million CAD | 94.442% |
1933 Industries Inc. | 23.28 Million CAD | 91.028% |
Red Light Holland Corp. | 3.82 Million CAD | 45.339% |
Top Strike Resources Corp. | 20.99 Million CAD | 90.05% |
Xebra Brands Ltd. | 789.95 Thousand CAD | -164.44% |
Adastra Holdings Ltd. | 17.65 Million CAD | 88.17% |